Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 17/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5164435 | 1.00 | SLC6A1 (0.78) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL10968404 | 1.00 | SLC6A1 (0.78) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL7357067 | 0.94 | SLC6A1 (0.69) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL9773467 | 0.93 | ALDH1A1 (0.70) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL7363843 | 0.88 | SLC6A1 (0.60) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL7363842 | 0.88 | SLC6A1 (0.60) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL676997 | 0.88 | SLC6A1 (1.00) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL676998 | 0.88 | SLC6A1 (1.00) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL11290241 | 0.88 | SLC6A1 (0.59) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL11290239 | 0.88 | SLC6A1 (0.59) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1331933-B1 | TIAGABINE FOR THE TREATMENT OF DIABETIC NEUROPATHY | ABBOTT LAB (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20050267050-A1 | Compositions and methods for treating mdma-induced toxicity | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2005-12-01 | — | — | US | disclosed |
| US-6872734-B2 | Use of tiagabine for treatment of diabetic neuropathy and migraine | ABBOTT LABORATORIES (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1484977-A2 | COMPOSITIONS AND METHODS FOR TREATING MDMA-INDUCED TOXICITY | YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003077831-A2 | COMPOSITIONS AND METHODS FOR TREATING MDMA-INDUCED TOXICITY | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2003-09-25 | — | — | WO | disclosed |
| EP-1331933-A2 | THE USE OF TIAGABINE FOR TREATMENT OF DIABETIC NEUROPATHY AND MIGRAINE | Abbott Laboratories (US) | 2003-08-06 | — | — | EP | disclosed |
| EP-0823909-B1 | NOVEL HETEROCYCLIC CHEMISTRY | BRITISH TECH GROUP INT (GB) | 2002-09-11 | — | — | EP | disclosed |
| US-20020103236-A1 | Use of tiagabine for treatment of diabetic neuropathy and migraine | ABBVIE INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002038144-A2 | THE USE OF TIAGABINE FOR TREATMENT OF DIABETIC NEUROPATHY AND MIGRAINE | ABBOTT LABORATORIES (US) | 2002-05-16 | — | — | WO | disclosed |
| US-6071932-A | SUPPRESSING ABSORPTION OF GAMMA-AMINOBUTYRIC ACID FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | BRITISH TECHNOLOGY GROUP INTERCORPORATE LICENSING LIMITED (GB) | 2000-06-06 | — | — | US | disclosed |
| US-5010090-A | N-(butenyl substituted) azaheterocyclic carboxylic acids | NOVO NORDISK A/S. (DK) | 1991-04-23 | — | — | US | disclosed |
| EP-0374801-A2 | Novel N-sustituted azaheterocyclic carboxylic acids | NOVO NORDISK A/S (DK) | 1990-06-27 | — | — | EP | disclosed |
| US-4931450-A | Amino acid derivatives | NOVO INDUSTRI A/S (DK) | 1990-06-05 | — | — | US | disclosed |
| EP-0342635-A1 | Azacyclic carboxylic acid derivatives, their preparation and use | NOVO NORDISK A/S (DK) | 1989-11-23 | — | — | EP | disclosed |
| EP-0236342-A1 | AMINO ACID DERIVATIVES. | NOVO INDUSTRI AS (DK) | 1987-09-16 | — | — | EP | disclosed |
| EP-0231996-A2 | Novel amino acid derivatives | NOVO NORDISK A/S (DK) | 1987-08-12 | — | — | EP | disclosed |
| WO-1987000171-A1 | AMINO ACID DERIVATIVES | NOVO INDUSTRI A/S (DK) | 1987-01-15 | — | — | WO | disclosed |
| EP-0066456-B1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND THEIR ESTERS | SMITHKLINE BECKMAN CORPORATION (US) | 1985-04-24 | — | — | EP | disclosed |
| US-4383999-A | GAMMA-AMINOBUTYRIC ACID SEDATIVES, ANALGESTICS, ANTIEPILEPTIC, MUSCULAR AND PSYCHOLOGICAL DISORDERS | SMITHKLINE BECKMAN CORPORATION (US) | 1983-05-17 | — | — | US | disclosed |
| EP-0066456-A1 | N-substituted azaheterocyclic carboxylic acids and their esters | SMITHKLINE BECKMAN CORPORATION (US) | 1982-12-08 | — | — | EP | disclosed |